Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market


#93404

114pages

GBI Research

$ 3500

In Stock


GBI Research’s new report, “Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market”, provides in-depth analysis of the unmet need, drivers and barriers impacting the global hepatitis market. The report analyzes the hepatitis markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. 

Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research has found that the global hepatitis market is one of the fast growing markets of the pharmaceutical industry. The approval of potential new drugs and combinational therapies with significant efficacy, safety and resistance profiles will fuel the rapid uptake of drugs in the near future. Limitations of the current standard care therapy for hepatitis include high incidence of adverse events, long duration of treatment, suboptimal patient compliance and the lack of efficacy in specific genotypes. This has increased interest in developing novel products able to potentially counter this unmet need.

Scope

  • Annualized market data for the hepatitis market from 2002 to 2010, forecast forward to 2017.
  • Analysis of the leading segments, including hepatitis A, hepatitis B and hepatitis C.
  • Analysis of the hepatitis market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
  • Market characterization of the hepatitis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
  • Key drivers and barriers that have a significant impact on the market.
  • Coverage of pipeline molecules in various Phases of drug development.
  • Competitive benchmarking of leading companies. The key companies studied in this report are Merck & Co, GlaxoSmithKline and F. Hoffman-La Roche.
  • Key M&A activities, licensing agreements that have taken place between 2009 and mid-2011 in the global hepatitis market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Global Hepatitis Market - Introduction
2.1 GBI Research Report Guidance

3 Global Hepatitis Market - Market Overview
3.1 Introduction
3.2 Global Hepatitis Therapeutics and Vaccines Market
3.3 Revenue Forecasts for the Global Hepatitis Therapeutics Market
3.3.1 Revenue
3.3.2 Annual Cost of Therapy
3.3.3 Treatment Usage Patterns
3.4 Hepatitis Market Drivers
3.4.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline
3.4.2 Promising Developments in Hepatitis C Pipeline
3.4.3 Steady Increase in Prescription Population
3.5 Hepatitis Market Restraints
3.5.1 Hepatitis Rarely Recognized during the Early Stages of the Disease
3.5.2 Low Treatment Seeking Population
3.5.3 Loss of Exclusivity Protection in Hepatitis B Market
3.6 Generic Share in the Global Hepatitis Therapeutics Market

4 Global Hepatitis Market - Therapeutic Landscape
4.1 Introduction
4.1.1 Hepatitis A
4.1.2 Hepatitis B
4.1.3 Hepatitis C
4.2 Overview of Hepatitis A and B Vaccines Market
4.2.1 Revenue
4.3 Hepatitis B Therapeutics Market
4.3.1 Revenue
4.3.2 Annual Cost of Therapy
4.3.3 Treatment Usage Patterns
4.3.4 Geographical Segmentation
4.4 Hepatitis C Therapeutics Market
4.4.1 Revenue
4.4.2 Annual Cost of Therapy
4.4.3 Treatment Usage Pattern
4.4.4 Geographical Segmentation

5 Global Hepatitis Market - Geographical Landscape
5.1 Geographical Break-up
5.2 The US Hepatitis Therapeutics Market
5.2.1 Revenue
5.2.2 Annual Cost of Therapy
5.2.3 Treatment Usage Patterns
5.3 Top Five Countries in Europe Hepatitis Therapeutics Market
5.3.1 Revenue
5.3.2 Annual Cost of Therapy
5.3.3 Treatment Usage Patterns
5.4 Japan Hepatitis Therapeutics Market
5.4.1 Revenue
5.4.2 Annual Cost of Therapy
5.4.3 Treatment Usage Patterns

6 Global Hepatitis Market - Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline - Hepatitis A Vaccines
6.1.2 Research and Development Pipeline - Hepatitis B Therapeutics
6.1.3 Research and Development Pipeline - Hepatitis B Vaccines
6.1.4 Research and Development Pipeline - Hepatitis C Therapeutics
6.2 Molecule Profile for Promising Vaccines for Hepatitis B under Clinical Development
6.2.1 Heplisav
6.2.2 Spi-VEC
6.3 Molecule Profile for Promising Therapeutics for Hepatitis B under Clinical Development
6.3.1 Entecavir plus Adefovir Combination Therapy
6.3.2 Tenofovir plus Emtricitabine Combination Therapy
6.3.3 Pegylated Interferon Alfa-2a + Adefovir
6.4 Molecule Profile for Promising Therapeutics for Hepatitis C under Clinical Development
6.4.1 Tenofovir + Emtricitabine Combination Therapy
6.4.2 Zalbin (albinterferon alfa-2b, Joulferon)
6.4.3 RG 7128

7 Global Hepatitis Market - Competitive Landscape
7.1 Market Share Analysis: Hepatitis
7.2 Competitive Profiling
7.2.1 Merck & Co., Inc.
7.2.2 F. Hoffmann-La Roche Ltd.
7.2.3 GlaxoSmithKline plc

8 Global Hepatitis Market - Strategic Consolidations
8.1 Mergers and Acquisitions
8.1.1 Overview
8.1.2 Summary of M&A Deals (2010-2011)
8.2 R&D Licensing Agreements
8.2.1 Summary of Licensing Deals (2010-2011)
8.3 Co-Development Deals

9 Global Hepatitis Market - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.4 Therapeutic Landscape
9.4.2 Market Size by Geography
9.5 Geographical Landscape
9.6 Pipeline Analysis
9.7 Competitive Landscape
9.7.1 Expert Panel Validation
9.8 Contact Us
9.9 Disclaimer
Table 1: Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2002-2010
Table 2: Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2010-2017
Table 3: Hepatitis Therapeutics Market, Global, Revenues ($m), 2002-2010
Table 4: Hepatitis Therapeutics Market, Global, Revenues ($m), 2010-2017
Table 5: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 6: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 7: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern (‘000s), 2002-2010
Table 8: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern (‘000s), 2010-2017
Table 9: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2002-2010
Table 10: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2010-2017
Table 11: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2002-2010
Table 12: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2010-2017
Table 13: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 14: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 15: Hepatitis B Therapeutics Market, Global, Treatment Usage Pattern, 2002-2010
Table 16: Hepatitis B Therapeutics Market, Global, Treatment Usage Patterns, 2010-2017
Table 17: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2010
Table 18: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2010-2017
Table 19: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2002-2010
Table 20: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2010-2017
Table 21: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 22: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 23: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2002-2010
Table 24: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2010-2017
Table 25: Hepatitis C Therapeutics Market, Global, Geographical Segmentation, 2002-2010
Table 26: Hepatitis C Therapeutics Market, Global, Geographical Segmentation, 2010-2017
Table 27: Hepatitis Market, Global, Revenue by Geography ($m), 2002-2010
Table 28: Hepatitis Market, Global, Revenue by Geography ($m), 2010-2017
Table 29: Hepatitis Therapeutics Market, The US, Revenue ($m), 2002-2010
Table 30: Hepatitis Therapeutics Market, The US, Revenue Forecasts ($m),2010-2017
Table 31: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2010
Table 32: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017
Table 33: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern (‘000s), 2002-2010
Table 34: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern (‘000s), 2010-2017
Table 35: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2010
Table 36: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2010-2017
Table 37: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010
Table 38: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017
Table 39: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (‘000s), 2002-2010
Table 40: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (‘000s), 2010-2017
Table 41: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2002-2010
Table 42: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2010-2017
Table 43: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010
Table 44: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017
Table 45: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (‘000s), 2002-2010
Table 46: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (‘000s), 2010-2017
Table 47: Hepatitis B Therapeutics Market, Global, Pipeline, 2011
Table 48: Hepatitis B Vaccines Market, Global, Pipeline, 2011
Table 49: Hepatitis C Therapeutics Market, Global, Pipeline, 2011

Figure 1: Hepatitis Market, Global, Drivers and Restraints, 2011
Figure 2: Hepatitis Market, Hepatitis Treatment Flow Pathway, 2017
Figure 3: Hepatitis Market, Global Therapeutics and Vaccines Market, Revenues ($m), 2002-2017
Figure 4: Hepatitis Therapeutics Market, Global, Revenues ($m), 2002-2017
Figure 5: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 6: Hepatitis Therapeutics Market, Global, Therapeutic Usage Pattern, 2002-2017
Figure 7: Hepatitis Therapeutics Market, Global, Diseased Population (‘000s), 2002-2017
Figure 8: Hepatitis Therapeutics Market, Global, Treatment Seeking Population (‘000s), 2002-2017
Figure 9: Hepatitis Therapeutics Market, Global, Diagnosed Population (‘000s), 2002-2017
Figure 10: Hepatitis Therapeutics Market, Global, Prescription Population (‘000s), 2002-2017
Figure 11: Hepatitis Therapeutics Market, Global, Branded and Generic Share (%), 2010-2017
Figure 12: Hepatitis Market, Global, Hepatitis B-Genotypes Based on Geographic Origin
Figure 13: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2002-2017
Figure 14: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2002-2017
Figure 15: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 16: Hepatitis B Therapeutics Market, Global, Treatment Usage Pattern, 2002-2017
Figure 17: Hepatitis B Therapeutics Market, Global, Diseased Population (‘000s), 2002-2017
Figure 18: Hepatitis B Therapeutics Market, Global, Treatment Seeking Population (‘000s), 2002-2017
Figure 19: Hepatitis B Therapeutics Market, Global, Diagnosed Population (‘000s), 2002-2017
Figure 20: Hepatitis B Therapeutics Market, Global, Prescription Population (‘000s), 2002-2017
Figure 21: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017
Figure 22: Hepatitis B Therapeutics Market, Global, Geography Benchmarking, 2010
Figure 23: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2002-2017
Figure 24: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 25: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2002-2017
Figure 26: Hepatitis C Therapeutics Market, Global, Diseased Population (‘000s), 2002-2017
Figure 27: Hepatitis C Therapeutics Market, Global, Treatment Seeking Population (‘000s), 2002-2017
Figure 28: Hepatitis C Therapeutics Market, Global, Diagnosed Population (‘000s), 2002-2017
Figure 29: Hepatitis C Therapeutics Market, Global, Prescription Population (‘000s), 2002-2017
Figure 30: Hepatitis C Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017
Figure 31: Hepatitis C Therapeutics Market, Global, Geography Benchmarking, 2010
Figure 32: Hepatitis Market, Global, Revenue by Geography ($m), 2002-2017
Figure 33: Hepatitis Market, Global, Geography Benchmarking, 2010 and 2017
Figure 34: Hepatitis Therapeutics Market, The US, Revenue ($m), 2002-2017
Figure 35: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2017
Figure 36: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern, 2002-2017
Figure 37: Hepatitis Therapeutics Market, The US, Diseased Population (‘000s), 2002-2017
Figure 38: Hepatitis Therapeutics Market, The US, Treatment Seeking Population (‘000s), 2002-2017
Figure 39: Hepatitis Therapeutics Market, The US, Diagnosed Population (‘000s), 2002-2017
Figure 40: Hepatitis Therapeutics Market, The US, Prescription Population (‘000s), 2002-2017
Figure 41: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2017
Figure 42: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017
Figure 43: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern, 2002-2017
Figure 44: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diseased Population (‘000s), 2002-2017
Figure 45: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population (‘000s), 2002-2017
Figure 46: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diagnosed Population (‘000s), 2002-2017
Figure 47: Hepatitis Therapeutics Market, Top Five Countries in Europe, Prescription Population (‘000s), 2002-2017
Figure 48: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2002-2017
Figure 49: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2017
Figure 50: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern, 2002-2017
Figure 51: Hepatitis Therapeutics Market, Japan, Diseased Population (‘000s), 2002-2017
Figure 52: Hepatitis Therapeutics Market, Japan, Treatment Seeking Population (‘000s), 2002-2017
Figure 53: Hepatitis Therapeutics Market, Japan, Diagnosed Population (‘000s), 2002-2017
Figure 54: Hepatitis Therapeutics Market, Japan, Prescription Population (‘000s), 2002-2017
Figure 55: Hepatitis Market, Global, R&D Pipeline by Indication (%), 2011
Figure 56: Hepatitis Market, Global, R&D Pipeline by Phase (%), 2011
Figure 57: Hepatitis B Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011
Figure 58: Hepatitis B Vaccines Market, Global, R&D Pipeline by Phase (%), 2011
Figure 59: Hepatitis C Therapeutics Market Global, R&D Pipeline by Phase (%), 2011
Figure 60: Hepatitis B and Hepatitis C Therapeutics Market, Global, Market Share of Top Players (%), 2010
Figure 61: Hepatitis Vaccines Market, Global, Market Share of Top Players (%), 2010
Figure 62: Hepatitis Market, Merck & Co., Inc., SWOT Analysis, 2011
Figure 63: Hepatitis Market, F. Hoffmann-La Roche Ltd., SWOT Analysis, 2011
Figure 64: Hepatitis Market, GlaxoSmithKline plc, SWOT Analysis, 2011
Figure 65: Hepatitis Therapeutics and Vaccines Market, Global, M&A Deals by Geography (%), 2011
Figure 66: Hepatitis Therapeutics and Vaccines Market, M&A Deals by Type (%), 2011
Figure 67: Hepatitis Market, Global, Major Licensing Agreements by Indication (%), 2011
Figure 68: Hepatitis Market, Global, Major Co-Development Deals by Indication (%), 2011
Figure 69: GBI Research Market Forecasting Model